Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib for residual postoperative ground-glass nodules in EGFR-mutant multiple primary lung cancer
ChiCTR2400085155Phase 4Not yet recruiting
- Sponsor
- Army Medical University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in multiple primary lung cancer (MPLC) and bronchial carcinoma comparing Furmonertinib treatment group with Observation group (2 arms). Primary endpoint: Patient response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
multiple primary lung cancer (MPLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2400085155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085155.